TAPAZOLE TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

METHIMAZOLE

Pieejams no:

PALADIN LABS INC.

ATĶ kods:

H03BB02

SNN (starptautisko nepatentēto nosaukumu):

THIAMAZOLE

Deva:

5MG

Zāļu forma:

TABLET

Kompozīcija:

METHIMAZOLE 5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

ANTITHYROID AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0104552001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2001-01-18

Produkta apraksts

_ _
_TAPAZOLE_
_®_
_ (methimazole tablets) Product Monograph _
_Page 1 of 19_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TAPAZOLE®
Methimazole
Tablets, 5 mg and 10 mg, oral
Manufacturer’s Standard
Antithyroid Agent
Paladin Labs Inc.
100 Alexis Nihon Blvd., Suite 600
Saint-Laurent, Quebec, Canada
H4M 2P2
paladinlabs.com
_ _
Date of Initial Authorization:
DEC 31, 1951
Date of Revision:
APR 13, 2023
Version 8.0
Submission Control Number: 270311
_ _
_TAPAZOLE_
_®_
_ (methimazole tablets) Product Monograph _
_Page 2 of 19_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic
06/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
..............................................